Drug Trial Radar · NCT05799157
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Feb 28, 2023
Primary completion
Feb 25, 2025
Study completion Feb 25, 2025
Sponsor
- Lead sponsor
- Veradermics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Conditions
- Verruca Vulgaris
- Warts
- Common Wart
Interventions
VDMN-21 Patch Low DoseDrug
Microneedle patch containing 125 mcg of active drug
VDMN-21 Patch High DoseDrug
Microneedle patch containing 250 mcg of active drug
Vehicle PatchDrug
Placebo microneedle patch containing no active drug (i.e., placebo)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment periodTime frame: Baseline up to Day 134
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Site 07
Fort Smith, Arkansas
Site 16
San Diego, California
Site 02
Plainfield, Indiana
Site 13
Louisville, Kentucky
Site 15
Baton Rouge, Louisiana
Site 09
New Brighton, Minnesota
Site 01
Anderson, South Carolina
Site 06
Greenville, South Carolina
Site 11
Knoxville, Tennessee
Site 03
Arlington, Texas
Site 04
Austin, Texas
Site 10
College Station, Texas
Site 12
Houston, Texas
Site 05
Pflugerville, Texas
Site 14
Norfolk, Virginia
Site 08
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.